Last reviewed · How we verify
NCT03094819
PROTECT2: Diabetes Care - Eye Exam
NA trial testing Financial Incentive in Diabetic Retinopathy in 4,500 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | Retinal Care Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | health services research |
| Enrollment | 4,500 |
| Start date | 17 March 2016 |
| Primary completion | 30 June 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Financial Incentive
- Retinal Care DR
Conditions studied
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
- Diabetic Macular Edema — all drugs for Diabetic Macular Edema →
Sponsor
Retinal Care Inc.
Who can join
Adults 18 to 75, any sex, with Diabetic Retinopathy or Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PROTECT2 pilot study is a single cohort prospective study to gather pilot data and finalize operational details of the main study. The PROTECT2 main study is a prospective randomized controlled multi-center three group clinical trial. The primary endpoint is the percentage of participants in each study group obtaining a qualified eye examination within 12 months of their enrollment in the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03094819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Financial Incentive
Trials testing the same drug.
- NCT07218120 — In-Person Recruitment of Individuals to the Alzheimer's Prevention Trial (APT) Webstudy · NA · recruiting
- NCT06300242 — Incentives for Influenza Vaccination · NA · completed
- NCT06234371 — Financial Incentives for Veteran Therapy Completion · NA · enrolling by invitation
- NCT06133816 — Lung Cancer Screening Eligibility Assessment · NA · completed
- NCT05648773 — COVID-19 Booster Incentives · NA · completed
Other recruiting trials for Diabetic Retinopathy
Currently open trials in the same condition.
- NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes · NA · recruiting
- NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06713720 — Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy · NA · recruiting
- NCT06892353 — AI-Powered DIY Screening System for Diabetic Retinopathy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03094819 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Retinal Care Inc.
- Last refreshed: 29 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03094819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing